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Effect of cilostazol and pentoxifylline on gait
biomechanics in rats with ischemic left hindlimb
Matheus Bredarioli, MD,a Marcelo Bellini Dalio, MD, PhD,a Edwaldo Edner Joviliano, MD, PhD,a
Willian Alves do Prado, MD, PhD,b and Carlos Eli Piccinato, MD, PhD,a Ribeirão Preto, Brazil
Objective: The purpose of this study was to determine the impact of pharmacologic treatment with cilostazol and
pentoxifylline on gait biomechanics of ischemic rat hindlimbs compared with nonischemic controls.
Methods: An experimental study was designed using 30 Wistar rats divided into five groups (n  6): control (C); ischemia
(I) – animals submitted to left common iliac artery interruption without pharmacologic treatment; pentoxifylline (Pen) –
rats submitted to procedure and treated with pentoxifylline 3 mg/kg twice a day for 6 weeks; cilostazol (Cil) – animals
submitted to procedure and treated with cilostazol 30 mg/kg twice a day for 6 weeks; and sham (S) – animals submitted
to procedure without artery interruption. Gait analysis was performed using a computed treadmill. Time, number, and
duration of each hindlimb contact were obtained. The total number of contacts (TNC) and the total duration of contacts
(TDC) were compared between left and right hindlimb and among groups. Left hindlimb ischemic incapacitation index
(LHII) was defined by the formula:
LHII 1 TNCleft TDCleftTNCright TDCright 100
Results: Left hindlimb TNC values were twofold lower in I, Pen, and Cil groups than in C and S groups (P < .01). In I,
Pen, and Cil groups, TNC values for the left hindlimb were half of the right hindlimb ones (P< .01). Left hindlimb TDC
values were lower in I and Pen groups than the other groups (P< .01). Cil group presented twofold increased values, not
different from C and S groups (P  0.16). Right hindlimb TNC values were greater for I group (P < .01). LHII was
around zero in C and S groups and 82 in both I and Pen groups (P< .01). Cil group presented a LHII of 42; higher than
C and S groups, but lower than I and Pen groups (P < .01).
Conclusions: Cilostazol at a dose of 30 mg/kg twice a day promoted improvement in gait performance in rats submitted
to chronic hindlimb ischemia. Pentoxifylline at a dose of 3mg/kg twice a day did not show this effect. ( J Vasc Surg 2012;
56:476-81.)
Clinical Relevance: Two medications are mostly used for treatment of intermittent claudication: cilostazol and pentoxi-
fylline. Changes in gait biomechanics have been poorly documented as a result of pharmacologic treatment in these
patients. Established experimental studies with animal models of ischemia described effects of medications on maximal
distance of deambulation. No study used analysis of gait biomechanics as parameter of evaluation of the effect of
pentoxifylline and cilostazol on intermittent claudication. The purpose of this study was to determine the impact of
pharmacologic treatment with cilostazol and pentoxifylline on gait biomechanics of ischemic rat hindlimb compared with
nonischemic controls.
Intermittent claudication (IC) is a common symptom
experienced by patients with peripheral arterial disease
(PAD).1 It has been shown that IC is associated with
alterations of gait characteristics.2
Two medications are mostly used for treatment of
intermittent claudication secondary to PAD: cilostazol and
pentoxifylline.3,4 Although the purpose of these medica-
tions is to eliminate symptoms and improve the distance
walked by patients with symptomatic PAD, changes in gait
biomechanics have been poorly documented as a result of
pharmacologic treatment in PAD patients.
Established experimental studies with animal models of
ischemia described effects of medications on maximal dis-
tance of deambulation.5,6 Gait biomechanics was altered in
rats submitted to limb ischemia.7 However, no study used
analysis of gait biomechanics as a parameter of evaluation of
the effect of pentoxifylline and cilostazol on IC.
The purpose of this study was to determine the impact
of pharmacologic treatment with cilostazol and pentoxifyl-
line on gait biomechanics of ischemic rat hindlimb com-
pared with nonischemic controls.
METHODS
Animals. Thirty male Wistar rats (University of São
Paulo, Ribeirão Preto, Brazil), weighing 100 to 150 g and
clinically healthy were used for this study. Animals were
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maintained in a room controlled for temperature and light
and were provided food and water ad libitum. Animal care
complied with the Principles of Laboratory Animal Care
(formulated by the National Society for Medical Research)
and the Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, Commission
on Life Sciences, National Research Council, Washington,
DC, National Academy Press, 1996). All protocols were
approved in accordance with the Animal Experimentation
Ethics Committee at University of São Paulo–Ribeirão
Preto, Brazil.
To become acclimated with the treadmill protocol,
animals were subjected to progressive training for 3 con-
secutive days. On the first day, animals were set on the
treadmill without movement for 10 minutes. On the sec-
ond day, they were exercised for 10 minutes with progres-
sive speed ranging from 5 to 12 m min1. On the third day,
they were exercised with speed of 12 m min1 and preop-
erative gait recordings were obtained. Rats that did not
adapt to this protocol were excluded (33%).
Experimental design. After the treadmill training, an-
imals were randomly divided in five groups (n 6): control
(C) – rats not submitted to any procedure; ischemia (I) –
animals submitted to ischemia-inducing procedure without
pharmacologic treatment; pentoxifylline (Pen) – rats sub-
mitted to procedure and treated with pentoxifylline 3
mg/kg twice a day for 6 weeks;8,9 cilostazol (Cil) – animals
submitted to procedure and treated with cilostazol 30
mg/kg twice a day for 6 weeks, utilizing 2% gum arabic as
vehicle;6 and sham (S) – animals submitted to procedure
without artery interruption. During the treatment phase,
animals were not exercised on the treadmill.
Rat hindlimb ischemia model. Anesthesia was in-
duced with intraperitoneal 10% ketamine (0.1 mL/100 g
body weight) and 10% xylasine (0.05 mL/100 g body
weight). Hindlimb ischemia was induced by left common
iliac artery interruption, following the surgical procedure
described in detail elsewhere.9 Careful dissection was per-
formed not to damage nerves and lymphatic vessels. No
heparin or antiplatelet agents were given. In the sham
group, the procedure was done without artery interruption.
Computed treadmill gait analysis. A computed
treadmill developed at University of São Paulo, Depart-
ment of Pharmacology of Faculty of Medicine of Ribeirão
Preto was utilized for gait analysis. It consisted of a moving
belt made of a mesh of stainless steel, which transmitted
electric impulses. Light electrodes (0.1 g) were symmetri-
cally placed in each animal’s hindlimbs with adhesive tape.
As the animals walked on the stainless steel mesh, contacts
between each hindlimb and the moving surface were regis-
tered. Time, number, and duration (ms) of each contact
were obtained. Data were analyzed by specially developed
software. Animal’s gait pattern was analyzed by plotting
cumulative contacts vs time for each hindlimb. The sum of
total number of contacts (TNC) and the total duration of
contacts (TDC) were compared between left and right
hindlimbs and among groups. Ischemic incapacitation was
defined as the deficiency of the ischemic limb to contribute
to animal gait. Quantification of ischemic incapacitation
was done comparing TNC and TDC between both
hindlimbs. The left hindlimb ischemic incapacitation index
(LHII), which was compared among groups, was defined
by the formula:
LHII 1 TNCleft TDCleftTNCright TDCright 100
For gait analysis, animals were placed on the treadmill and
walked spontaneously for 5 minutes at a speed of 12m
min1 and angulation of 15°.
Statistical analysis. Data were expressed as the mean
the standard deviation. Statistical comparisons within and
among groups were done with mixed effects linear regres-
sion. Statistical comparisons between animal weight values
were done with Kruskal–Wallis one-way analysis of vari-
ance. A P value of less than .05 was considered statistically
significant.
RESULTS
Weight and clinical evaluation
There was no significant difference among groups be-
tween animal preprocedure weight values and after 6
weeks. Ulcers, tissue loss, and wound infection were not
observed in any animal after the procedure. In groups I,
Pen, and Cil, which were subjected to iliac artery interrup-
tion, pallor was observed during the first days that turned
progressively into cyanosis. This cyanosis was more evident
during exercise on the treadmill.
Gait analysis
Contact vs time. A separate analysis of a random
animal of ischemic and nonischemic groups for 120 sec-
onds, plotting each contact vs time for each hindlimb
generated a graph with two lines. In groups C and S, these
lines were parallel, whereas in groups I, Pen, and Cil, these
lines were divergent, with the line representing the left
hindlimb being below. A sample graph of an animal of S
group and I group is showed in Fig 1.
TNC. Comparing TNC between left and right
hindlimbs, groups C and S presented no significant differ-
ence. In I, Pen, and Cil groups, left hindlimbs had signifi-
cantly less contacts, evidencing a gait disturbance (Table I).
Comparing right hindlimb TNC among groups, there
was no significant difference. Left hindlimb TNC values
were significantly lower in I, Pen, and Cil groups than in C
and S groups (P .01). When compared separately, I, Pen,
and Cil groups were not different (Fig 2).
TDC. In C and S groups, TDC was not different
between left and right hindlimbs. In I, Pen, and Cil groups,
TDC values were significantly lower for left hindlimb when
compared with right hindlimb (Table II).
Left hindlimb TDC values were significantly lower in I
and Pen groups than the other groups (P .01). Cil group
presented higher values, not significantly different form C
and S groups (P  .16). Right hindlimb TDC values were
significantly greater for I group (Fig 3).
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LHII. LHII was significantly increased in I and Pen
groups compared with C and S groups (P .01). Cil group
presented a LHII significantly lower than I and Pen groups
(P .01) but higher than C and S groups (P .1) (Fig 4).
DISCUSSION
All knowledge on human IC is based on a biped model
of locomotion, in which gait is developed in two limbs.10
Gait disturbances in patients with chronic limb ischemia
were characterized by a decrease in speed, step length, and
cadence.11 The detection of gait disturbances resembling
intermittent claudication in quadruped animals implies
adopting a model that takes into consideration the mecha-
nisms of gait in four limbs.
The present study adopted the rat hindlimb ischemia
model as described by Hudlincka et al9 with addition of
methods of gait analysis described by Tonussi et al.12 These
authors used a computed treadmill to determine the func-
tional incapacitation caused by a mechanical lesion in the
rat knee. Time and number of each contact were used as
parameters of incapacitation. Models of hindlimb ischemia
models were previously described in rats.13-15
In the present investigation, ischemia was induced by
left common iliac artery interruption, since it per-
mitted comparisons between ischemic and nonischemic
hindlimbs. Midline abdominal incision was the access of
choice in order not to interfere in gait symmetry. Rochester
et al studied hemodynamic alterations caused by high left
common iliac artery interruption and determined that 6
weeks was the time to achieve chronic limb ischemia.16
Thus, this was the time chosen for the treadmill test after
the procedure.
Testing medications for treatment of intermittent clau-
dication was the main motivation of this study. In a previ-
ous animal study, authors used muscle exhaustion time for
testing medications, which was defined as animal inability
to continue treadmill gait.17 Another work used the maxi-
mum distance reached by a rat in a treadmill to study the
effect of a prostaglandin E1 analogue in a model of neuro-
logic claudication.18
In the present study, we used TNC and TDC as param-
eters of gait analysis. Left hindlimb TNC and TDC values
were lower in ischemic groups in comparison with nonisch-
emic ones (P  .01). Thus, the treadmill test was able to
distinguish ischemic and nonischemic animals. LHII is
relative quantity that correlates gait performance of the
ischemic limb with the contralateral one. Studying gait and
Fig 1. Plotting contact vs time for each hindlimb in sham (S) and ischemia and no treatment (I) groups. Straight line,
right hindlimb; interrupted line, left hindlimb.
Table I. Intragroup comparison of TNC of each
hindlimb
TNC
Groups
Right hindlimb
(mean  SD)
Left hindlimb
(mean  SD) P
C 647.67  93.43 655.50  50.46 .80
I 701.00  148.85 337.00  97.89 .01
Pen 623.50  62.94 252.50  59.88 .01
Cil 619.33  185.09 416.83  99.79 .01
S 559.33  51.84 587.00  65.35 .39
C, Control; Cil, ischemia and cilostazol; I, ischemia and no treatment; S,
sham; SD, standard deviation; Pen, ischemia and pentoxifylline; TNC, total
number of contacts.
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defining percent of usage of ischemic hindlimb, one can
estimate incapacitation generated by ischemia, and perform
comparisons within and among groups testing different
therapeutic options.
There was no weight difference among groups 6 weeks
after ischemia-inducing procedure. This fact, as well as the
absence of ulcers and tissue loss, supported that left com-
mon iliac artery interruption did not cause rest pain that
could lead the animal to starvation and weight loss.
TNC was compared within and among groups. In
nonischemic groups (C, S), TNC was the same for both
limbs, demonstrating that the sham procedure did not
impair the ability to walk. However, in ischemic groups (I,
Pen, and Cil), left hindlimb TNC values were lower than
right hindlimb ones, indicating that the system was sensi-
tive in detecting ischemic gait disturbances.
Comparing right hindlimb TNC among groups, no
difference was found. Since the rat is a tetrapod, there was
no overload on hind limbs, even in the ischemic groups.
These data suggest that forelimbs may contribute to this
compensation.
Besides being lower in all ischemic groups, left hindlimb
TNC values were equivalent in animals treated with cilostazol,
pentoxifylline, and in ischemic animals without treatment.
TNC, analyzed independently, did not show improvement in
gait performance in groups treated with cilostazol and pen-
toxifylline compared with ischemic groups.
In ischemic groups, TDC values were lower for left
hindlimbs than right hindlimbs, while in nonischemic ones
there was no significant difference between hindlimbs. This
was additional evidence that the system was sensitive in
detecting ischemic gait disturbances.
Comparison of right hindlimb TDC among groups
showed that ischemic animals had greater values than non-
ischemic ones. This suggested that animals favored the
nonischemic hindlimb (right) during deambulation. How-
ever, in the group treated with cilostazol, right hindlimb
TDC values were similar to those found in nonischemic
groups. This was not observed in the group treated with
pentoxifylline. Left hindlimb TDC values were greater in
nonischemic groups, except for the group treated with
cilostazol. Left hindlimb TDC values were not significantly
different between the Cil group and the nonischemic
groups (P  .16). These findings demonstrated that
cilostazol caused an improvement in gait performance.
By means of LHII, the global gait performance of hind
limbs could be evaluated. Animals treated with cilostazol
for 6 weeks had significant improvement in treadmill test.
Groups treated with pentoxifylline presented performance
equivalent to animals without treatment.
Orito et al also used an experimental model with tread-
mill tests in ischemic animals to evaluate IC.6 Their param-
eters were the distance walked without disturbance and
maximal walked distance. They demonstrated that cilosta-
zol at a dose of 30 mg/kg twice a day for 2 weeks increased
distance walked without gait disturbance and also maximal
walked distance. At a dose of 100 mg/kg, cilostazol did not
cause benefit, since it decreased systemic blood pressure.
In humans, clinical benefits of pentoxifylline are question-
able. This drug promoted only a modest increase in walked
distance in treadmill tests, and its use in IC lacks clinical
evidence.19 Cilostazol has a number of actions that may
contribute to the amelioration of chronic limb ischemia, such
Fig 2. Intergroup comparison of total number of contacts (TNC) of each hindlimb. C, Control; Cil, ischemia and
cilostazol; I, ischemia and no treatment; Pen, ischemia and pentoxifylline; S, sham; (—), mean; (□), confidence
interval; (‡), standard deviation.
Table II. Intragroup comparison of TDC of each
hindlimb
TDC
Groups Right hindlimb Left hindlimb P
C 139.50  27.37 137.33  30.26 .84
I 199.17  25.30 71.83  24.56 .01
Pen 153.50  24.17 61.50  22.41 .01
Cil 142.83  34.75 115.67  23.67 .01
S 141.50  20.05 137.50  22.23 .71
C, Control; Cil, ischemia and cilostazol; I, ischemia and no treatment; Pen,
ischemia and pentoxifylline; S, sham; SD, standard deviation; TDC, total
duration of contacts.
JOURNAL OF VASCULAR SURGERY
Volume 56, Number 2 Bredarioli et al 479
as the inhibition of platelet aggregation, which is caused by
inhibiting phosphodiesterase III20,21 and increasing blood
flow during reactive hyperemia.22,23 Strong clinical evidence
supports this drug as pharmacologic treatment for patients
with intermittent IC.24 A meta-analysis of 1751 patients dem-
onstrated clinical benefits of cilostazol. Treatment with
cilostazol was associated with greater improvements in walk-
ing ability and quality of life.25 A multicentric randomized trial
comparing clinical effects of cilostazol and pentoxifylline in IC
showed that cilostazol was significantly better than pentoxifyl-
line for increasing walking distances.26 Several other multicen-
tric studies and meta-analyses demonstrate that cilostazol
causes improvement of maximal walking distance and meta-
bolic parameters in IC.27-31
The findings of this study added evidence to the available
clinical data, contributing to the idea that cilostazol provides
benefits in the treatment of IC.32-35 Our study also concluded
that pentoxifylline has a limited role, and its use lacks clinical
and experimental evidence.36,37 The compatibility of the pres-
ent results with the available clinical data suggests that the
adopted model may be applicable for future studies. New
therapies for IC, such as drugs, gene therapy, or other molec-
ular strategies could be evaluated with this model.
There were some limitations of this work. Limb perfusion
was evaluated only on a clinical basis, with observation of
pallor and cyanosis. Objective measurements such as transcu-
taneous oxygen saturation and Doppler ultrasound were not
performed. Platelet function was also not studied. Gait speed
was not evaluated, but it is a promising new field of research
for future studies, which could bring improvement to the
model. Finally, anatomical and histologic examinations of the
ischemic hindlimbs were not performed after the euthanasia.
In conclusion, cilostazol at a dose of 30 mg/kg twice a
day promoted improvement in gait performance in rats
submitted to chronic hindlimb ischemia. Pentoxifylline at a
dose of 3 mg/kg twice a day did not show this effect.
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